热门资讯> 正文
学者洛克为其研究性肥胖候选人提供临床前数据
2024-06-24 21:22
- Scholar Rock (NASDAQ:SRRK) announced that the first participants were dosed in the mid-stage trial designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin inhibitor, to preserve lean muscle mass in individuals living with obesity.
- The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy.
- The group that received SRK-439 maintained more favorable body composition than the group receiving IgG antibody.
- Source: Press Release
More on Scholar Rock
- FOMC Meeting, Jobs Report, And Apple Earnings Headline Big Week
- Seeking Alpha’s Quant Rating on Scholar Rock
- Historical earnings data for Scholar Rock
- Financial information for Scholar Rock
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
